中国生物制药(01177.HK) 公布，集团和博奥信生物技术(南京)就联合开发的TSLP单克隆抗体“BSI-045B (TQC2731)”，与Aclaris Therapeutics, Inc. (ACRS.US) 达成全球合作协议。
据介绍，“BSI-045B (TQC2731)”是一款靶向胸腺基质淋巴细胞生成素(TSLP)的人源化单克隆抗体，可以阻止TSLP靶向的免疫细胞释放促炎细胞因子。目前，“BSI-045B (TQC2731)”正在中国开展III期临床试验，全球开展II期临床试验，适应症包括哮喘、慢性鼻窦炎伴有鼻息肉、特应性皮炎。
另外，Aclaris Therapeutics亦与博奥信生物技术(南京)达成许可协议，获得“BSI-045B (TQC2731)”和另一款临床前产品在全球(除中国大陆、澳门、香港、台湾)开发、生产和商业化的独家授权。
据合作协议及许可协议条款，Aclaris Therapeutics同意支付总计超过4,000万美元(下同)现金，作为首付款以及承担部分开发成本和药物产品材料费用；19.9%的股权(总价值近5,400万元)；总计潜在超过9亿元的研发及销售里程碑付款；单位数比例的销售分成。中国生物制药将获得以上交易对价的一部分。(js/u)
(港股报价延迟最少十五分钟。沽空资料截至 2024-12-05 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.